iRhythm Technologies Outperforms United Treatment Centers in Financial Contrast

Analysts see stronger potential upside for iRhythm's medical technology over United Treatment Centers' hemp-derived CBD products

Mar. 16, 2026 at 8:08am

Got story updates? Submit your updates here. ›

A financial analysis comparing medical technology company iRhythm Technologies (NASDAQ:IRTC) and hemp-CBD producer United Treatment Centers (OTCMKTS:POTN) shows iRhythm has stronger financial metrics, a more favorable analyst consensus, and greater potential upside according to price targets.

Why it matters

The contrast highlights the differing trajectories of the two companies, with iRhythm's cardiac monitoring devices seen as a more promising medical technology investment compared to United Treatment Centers' hemp-CBD product line in a crowded market.

The details

The analysis found that while United Treatment Centers has higher earnings, iRhythm Technologies generates more revenue. iRhythm also has stronger net margins, return on equity, and return on assets. Analysts give iRhythm a more favorable consensus rating and see 85% potential upside, compared to United Treatment Centers.

  • The analysis was published on March 16, 2026.

The players

iRhythm Technologies

A digital healthcare company that develops device-based technology for ambulatory cardiac monitoring services to diagnose arrhythmias.

United Treatment Centers

A company that engages in the development and sale of hemp-derived cannabidiol (CBD) oil products under various brands.

Got photos? Submit your photos here. ›

The takeaway

The analysis indicates iRhythm's medical technology is seen as a more promising investment opportunity compared to United Treatment Centers' hemp-CBD products, highlighting the differing trajectories and outlooks for the two companies in the healthcare and wellness sectors.